Boston Scientific Tumbles 0.94% as Volume Dives 26.54% to 186th Despite IBD Rating Surge to 71

On August 15, 2025, Boston Scientific (BSX) closed with a 0.94% decline, marking a daily trading volume of $0.55 billion—a 26.54% drop from the previous day and ranking 186th in market activity. The stock’s performance followed an upgrade in its IBD Relative Strength Rating, which rose to 71 from 66, reflecting improved momentum in its price action over the last 12 months. This rating, which measures stocks on a 1-to-99 scale, indicates BSX has outperformed 71% of its peers in relative strength metrics.

The upgrade signals potential investor confidence in Boston Scientific’s technical outlook, though the recent volume contraction suggests caution in the market. Analysts note that while the rating improvement may attract momentum-driven strategies, the lack of follow-through in trading activity highlights mixed sentiment ahead of broader catalysts. The stock’s performance remains closely tied to its ability to sustain above-average relative strength readings and convert technical momentum into fundamental gains.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to now delivered moderate returns. The 1-day return was 0.98%, with a total return of 31.52% over 365 days. The strategy's Sharpe ratio was 0.79, indicating good risk-adjusted returns. The highest daily return was 4.95%, and the lowest was -4.47%. This backtest shows the strategy's ability to capture short-term momentum while facing volatility in the stock market.